The OsteoPearl biologic allograft is made from 100% cortical bone and is designed to stabilize vertebral compression fractures, according to a May 9 news release. The investment will also expand clinical evidence and support development.
Xcellerant Ventures, Highpoint Ventures, Vodia Capital, RightHill Ventures and other groups were involved with funding.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
